Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Ivailo Tournev et al.|New England Journal of Medicine|2018Cited by 2.9k
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1Sander F. Garrelfs, John C. Lieske, Yaacov Frishberg et al.|New England Journal of Medicine|2021Cited by 505
LB002ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)Sander F. Garrelfs, John C. Lieske, Yaacov Frishberg et al.|Nephrology Dialysis Transplantation|2020Cited by 21